Table 1 General characteristics of the study subjects according to functional outcome.
Independent outcome (mRS 0–2) | Dependent outcome (mRS 3–6) | P-value | |
|---|---|---|---|
N | 200 | 292 | |
Age, mean (SD), yr | 66.3 (12.4) | 72.5 (11.3) | <0.001 |
Male, N (%) | 125 (62.5) | 156 (53.4) | 0.05 |
Initial NIHSS score (med, IQR) | 8 (5, 12) | 12 (9, 15.5) | <0.001 |
Time from onset to treatment, mean (SD), min | 133 (59) | 135 (59) | 0.72 |
SBP, mean (SD), mmHg | 137 (23) | 139 (25) | 0.23 |
TOAST, N (%) | 0.001 | ||
LAA | 45 (22.5) | 64 (21.9) | |
CE | 54 (27.0) | 125 (42.8) | |
SVO | 6 (3.0) | 3 (1.0) | |
UD | 95 (47.5) | 100 (34.2) | |
HTN | 113 (56.5) | 167 (57.2) | 0.93 |
DM | 40 (20.0) | 62 (21.2) | 0.82 |
AF | 20 (10.0) | 54 (18.5) | 0.01 |
Dyslipidemia | 15 (7.5) | 15 (5.1) | 0.34 |
Smoking | 59 (29.5) | 77 (26.4) | 0.47 |
Prior coronary disease | 14 (7.0) | 14 (4.8) | 0.33 |
Prior stroke or TIA | 14 (7.0) | 34 (11.6) | 0.09 |
Large artery occlusion | 119 (59.5) | 226 (77.4) | <0.001 |
MCA | 25 (12.5) | 34 (11.6) | |
Intracranial ICA | 47 (23.5) | 83 (28.4) | |
Extracranial ICA | 35 (17.5) | 84 (28.8) | |
Vertebrobasilar | 3 (1.5) | 14 (4.8) | |
Others | 9 (4.5) | 11 (3.8) | |
Endovascular therapy | 58 (29.0) | 73 (25.0) | 0.35 |
Insulin therapy | 13 (6.5) | 26 (8.9) | 0.40 |
Glucose parameters, median (IQR), mg/dl | |||
Mean blood glucose | 120.7 (106.5, 137.5) | 127.5 (112.5, 146) | 0.002 |
Initial blood glucose | 124 (101, 151) | 126 (107, 153) | 0.31 |
Maximal blood glucose | 152 (128, 188) | 156.5 (131.5, 181) | 0.43 |
Glycemic variability, median (IQR) | |||
Standard deviation, unit | 21 (12.5, 32.2) | 18 (12.5, 27) | 0.13 |
Coefficient of variance, % | 17 (11.2, 23.5) | 14.3 (10.2, 19.8) | 0.005 |
J index, unit | 20.2 (15.1, 27.3) | 21.7 (16.3, 28.8) | 0.11 |
